WHAT IS
ALZHEIMER’S
DISEASE?

WHAT IS ALZHEIMER’S DISEASE?

Alzheimer’s disease (AD) is the most common type of dementia among older adults. In the United States it is estimated that one in ten people aged 65 and older (10%) has Alzheimer’s dementia.

AD is an irreversible and progressive brain disorder that gradually destroys mental and cognitive skills. The initial symptoms of AD include memory problems, difficulty finding the right words, poor problem-solving skills, vision/spatial issues, as well as impaired reasoning or judgement. As the disease progresses, Alzheimer’s patients lose the ability to carry out the simplest tasks and become increasingly disconnected from their environment.

On a neurological level, AD affects the nerve cells (neurons) in the brain. The neurons transmit messages between different parts of the brain and from the brain to the rest of the body. AD hinders the communication between the neurons and also causes neurodegeneration and death. As a result, the brain’s functioning is severely hindered.

The earliest manifestations of AD are problems with short-term memory. As the disease progresses, more and more cognitive functions become impaired. In late stages of AD, the disease causes the malfunction and cell death in entire regions of the brain and the brain significantly shrinks in size. At a certain point the brain cannot control the most basic bodily functions such as swallowing or stable breathing, and eventually AD becomes fatal.

Immense resources have been invested in research and development to find a cure for AD. To date, no cure has been identified. In the interim, scientists have developed pharmacologic treatments which aim to slow down the progression of the disease and improve Alzheimer’s patients’ quality of life.

Neuronix is the only company in the world that has developed a medical device for the treatment of mild to moderate AD. We are proud to be part of the fight against AD, and excited to offer Alzheimer’s patients and their caregivers an additional treatment option.